The NTCC?BIN-67 cell line is a human cancer cell line derived from a metastatic pelvic nodule of a patient with ovarian small cell carcinoma of the hypercalcemic type (SCCOHT). It is a rare and highly aggressive form of ovarian cancer that typically affects young women. BIN-67 is one of the few available cell lines for this specific type of cancer, making it an invaluable tool for research.

Key Characteristics

• Origin: The cell line was established in 1986 from a metastatic lesion, not the primary tumor itself.

• Genetic Profile: Unlike many other ovarian cancers, the BIN-67 cell line exhibits a relatively stable genome with few chromosomal anomalies. It lacks common mutations in genes like TP53, KRAS, and BRAF. A key genetic feature is a loss-of-function mutation in the SMARCA4 gene, which is a highly specific and sensitive marker for SCCOHT.

• Biochemical Properties: A defining characteristic of the BIN-67 cell line is its high expression of calcitonin receptors (CTR). It responds to calcitonin stimulation with a significant increase in cyclic AMP (cAMP), a key signaling molecule. This response is linked to the hypercalcemia (high calcium levels) often seen in patients with this type of cancer.

• Therapeutic Response: BIN-67 cells are known to be resistant to many standard chemotherapeutic drugs, such as platinum-based agents. However, they have shown a sensitivity to oncolytic viruses in some studies, suggesting a potential alternative treatment pathway.

Research Applications

The BIN-67 cell line is a critical resource for studying SCCOHT, a cancer that is poorly understood due to its rarity. Researchers use this cell line to:

• Model SCCOHT: It serves as a representative model for the disease, allowing scientists to investigate its unique biological and genetic characteristics.

• Investigate Cancer Biology: The cell line is used to study the function of the SMARCA4 gene and the role of the SWI/SNF chromatin remodeling complex in tumor formation.

• Drug Development: It is a valuable tool for screening and testing new therapeutic agents and strategies, especially for a cancer that is largely resistant to conventional treatments.

BIN-67 細胞系是一種人類癌細胞系，源自一名患有**高鈣血癥型卵巢小細胞癌（SCCOHT）**患者的盆腔轉移性結節(jié)。SCCOHT 是一種罕見且高度侵襲性的卵巢癌，通常影響年輕女性。BIN-67 是目前針對這種特殊癌癥類型為數(shù)不多的可用細胞系之一，使其成為研究的寶貴工具。

主要特點

• 來源: 該細胞系于1986年從一個轉移性病灶而非原發(fā)腫瘤中建立。

• 遺傳學特征: 與許多其他卵巢癌不同，BIN-67 細胞系具有相對穩(wěn)定的基因組，染色體異常較少。它缺乏 TP53、KRAS 和 BRAF 等基因中常見的突變。其一個關鍵遺傳特征是 SMARCA4 基因的功能缺失性突變，這是 SCCOHT 的高度特異性及敏感性標志物。

• 生化特性: BIN-67 細胞系的一個決定性特征是其降鈣素受體 (CTR) 的高表達。它對降鈣素刺激反應強烈，會顯著增加關鍵信號分子——環(huán)磷酸腺苷 (cAMP) 的水平。這種反應與該類型癌癥患者常見的高鈣血癥（高鈣水平）相關。

• 治療反應: 已知 BIN-67 細胞對許多標準化療藥物（如鉑類藥物）具有耐藥性。然而，一些研究表明它們對溶瘤病毒敏感，這提示了一種潛在的替代治療途徑。

研究應用

由于 SCCOHT 罕見且鮮為人知，BIN-67 細胞系是研究該疾病的關鍵資源。研究人員利用該細胞系來：

• 模擬 SCCOHT: 它作為該疾病的一個代表性模型，使科學家能夠研究其獨特的生物學和遺傳學特征。

• 探究癌癥生物學: 該細胞系被用于研究 SMARCA4 基因的功能以及 SWI/SNF 染色質重塑復合物在腫瘤形成中的作用。

• 藥物開發(fā): 對于這種對常規(guī)治療大多具有耐藥性的癌癥，該細胞系是篩選和測試新治療藥物及策略的重要工具。

BioVector NTCC質粒載體菌種細胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: [email protected]

http://www.nedfriskphoto.com